We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Illumina

Illumina develops, manufactures and markets integrated systems for the analysis of genetic variations and biological ... read more Featured Products: More products

Download Mobile App




Phoenix CPO Test Evaluated for Detection of Carbapenemase Producers

By LabMedica International staff writers
Posted on 14 Nov 2019
The use of nucleic acid amplification tests (NAAT) to identify rapidly Carbapenemase-Producing Organisms (CPO) from samples such as positive blood culture and stools is an alternative approach to establish rapidly an optimal empirical antibiotic therapy or for infectious control management.

Most carbapenemase NAAT panels detect the most frequent gene variants encoding for carbapenemases including KPC, NDM, OXA-48, VIM and IMP. More...
However, these tests cannot exclude the presence of a gene encoding another carbapenemase type and are relatively expensive, hence preventing their use to screen systematically some specimen types or bacterial isolates with CPO suspicion, especially in low to very low prevalence countries.

Medical microbiologists at the Lausanne University Hospital (Lausanne, Switzerland) tested the performance of the Phoenix CPO Detect Test (Becton-Dickinson, Franklin Lakes, NJ, USA) on a collection of 92 molecularly-characterized CPO and 93 non-CPO. The collection included 27 non-fermentative bacteria and 158 Enterobacterales. In addition, 295 clinical isolates, including 135 isolates with suspected carbapenemase, were prospectively, but not consecutively isolated from various de-identified clinical specimens during a 10 months period ranging from January to October 2018.

MALDI-TOF was used as an additional phenotypic test to exclude the presence of carbapenemase activity in Phoenix CPO Detect test false positives. All false positive results of the Phoenix CPO Detect test from the prospective study were verified by NAAT testing using the BD MAX Check-Points CPO test. Whole genome sequencing and analysis with libraries prepared with the Nextera XT kit (Illumina, San Diego, USA).

In a retrospective study the scientists reported the Phoenix CPO test exhibited 92.4% accuracy, 97.8% sensitivity 87.1% specificity for carbapenemase detection. The Phoenix CPO test provided a classification to class A, B, and D for 81.3% of detected carbapenemases with 94.6% accuracy. In a prospective study, the CPO test detection performance showed 77.8% accuracy, 100% sensitivity and 67.8% specificity on 135 CPO suspicious isolates and 98.8% accuracy and specificity on 160 non-CPO suspicious isolates. Compared to routine testing, the implementation of the CPO test allowed a mean reduction of 21.3 hours in turnaround time (TAT), 16.8 minutes) in hands-on time (HOT), and CHF 20.6 in costs.

The authors concluded that the Phoenix CPO Detect test likely represents a new diagnostic tool with added value for the detection and management of CPO infection and colonization. The CPO test is reliable for the detection of CPO with a high sensitivity but the relatively low specificity requires the use of additional confirmatory methods. The carbapenemase classification accuracy is robust to provide preliminary results before molecular characterization. The study was published on October 18, 2019 in the journal Clinical Microbiology and Infection.

Related Links:
Lausanne University Hospital
Becton-Dickinson
Illumina



New
Gold Member
Automated MALDI-TOF MS System
EXS 3000
Portable Electronic Pipette
Mini 96
Urine Chemistry Control
Dropper Urine Chemistry Control
New
Gold Member
Hybrid Pipette
SWITCH
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: The CloneSeq-SV approach can allow researchers to study how cells within high-grade serous ovarian cancer change over time (Photo courtesy of MSK)

Blood Test Tracks Treatment Resistance in High-Grade Serous Ovarian Cancer

High-grade serous ovarian cancer (HGSOC) is often diagnosed at an advanced stage because it spreads microscopically throughout the abdomen, and although initial surgery and chemotherapy can work, most... Read more

Industry

view channel
Image: The collaboration aims to improve access to Hb variant testing with the Gazelle POC diagnostic platform (Photo courtesy of Hemex Health)

Terumo BCT and Hemex Health Collaborate to Improve Access to Testing for Hemoglobin Disorders

Millions of people worldwide living with sickle cell disease and other hemoglobin disorders experience delayed diagnosis and limited access to effective care, particularly in regions where testing is scarce.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.